Eli Lilly stock slips again as April orforglipron decision and FDA GLP-1 ad crackdown loom
Eli Lilly and Company wrapped up Tuesday’s session down roughly 1%, settling at $1,007.73. That followed a 3.23% drop the previous day.
Ventyx stock jumps on Lilly’s $1.2 billion buyout — and why it’s still trading under $14
Shares of Ventyx Biosciences jumped on Wednesday after Eli Lilly agreed to buy the San Diego-based biotech in a $14-per-share all-cash deal. Ventyx closed up about 37% at $13.81 and was last at $13.73 in after-hours trading, still shy of the offer price. Yahoo Finance
Ventyx Biosciences stock jumps premarket as Eli Lilly buyout talks fuel takeover buzz
Ventyx Biosciences shares jumped about 66% before the bell on Wednesday after a report that Eli Lilly is in advanced talks to buy the biotech company for more than $1 billion. The stock traded at $16.70 in premarket action, versus a $10.05 regular-session close. Public
Ventyx Biosciences (VTYX) Stock Rockets on Breakthrough Inflammation Study – Analysts Bullish
Ventyx Biosciences has been one of 2025’s biggest small-cap biotech movers. The Nasdaq-listed stock jumped sharply on Oct. 22 after hours, when the company announced the positive Phase 2 data. On Oct. 22 regular trading, VTYX ended at $3.86 marketbeat.com, but in electronic after-hours trading it skyrocketed roughly 85–90%, touching the low $7’s marketbeat.com benzinga.com. By early Oct. 23 the stock was quoting around $3.86, reflecting profit-taking after the spike. Over the past six months, the stock had already climbed over 230%, driven by pipeline optimism benzinga.com. Analysts note that before the news, shares were near the bottom of their 52-week range and have now hit multi‑year highs.